Post-market Study to Obtain Surgeon Feedback on Clinical Outcome in Eyes Implanted With TECNIS Toric II IOL

Inclusion criteria

• Unilateral or bilateral cataracts for which phacoemulsification extraction and posterior chamber IOL implantation have been planned;
• Preoperative corneal astigmatism of one diopter or more in the operative eye;
• Potential for postoperative best corrected distance visual acuity (BCDVA) of 20/30 Snellen or better;
• Clear intraocular media other than cataract in each eye;
• Ability to understand, read and write English in order to consent to study participation;
• Availability, willingness, sufficient cognitive awareness to comply with examination procedures;
• Signed Informed Consent Document (ICD) and Health Insurance Portability and Accountability Act (HIPAA) authorization.

Exclusion criteria

• Recurrent severe anterior or posterior segment inflammation or uveitis;
• Compromised eye due to previous trauma or developmental defects in which appropriate support of the IOL is not possible;
• Circumstances that would result in damage to the endothelium during implantation;
• Suspected ocular microbial infection;
• Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration, including pseudoexfoliation, trauma, or posterior capsule defects;
• Known ocular disease or pathology that, in the opinion of the investigator, may affect visual acuity or require surgical intervention during the course of the study, [macular degeneration, cystoid macular edema, proliferative diabetic retinopathy (severe), uncontrolled glaucoma, irregular corneal astigmatism, choroidal hemorrhage, concomitant severe eye disease, extremely shallow anterior chamber, microphthalmos, non-age related cataract, severe corneal dystrophy, severe optic nerve atrophy, etc.];
• Planned monovision correction;
• Concurrent participation or participation within 30 days prior to the preoperative visit in any other clinical study.